On the other hand, leptin therapy can resolve hepatic steatosis and ultimately improve insulin function (36). In a biopsy-proven NAFLD study, a portion of lean people may also develop MAFLD, which may be related to visceral fat obesity (37). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.